Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $16.50.

A number of analysts have commented on IMRX shares. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday, June 24th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research note on Monday, March 9th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st.

Immuneering Stock Performance

Shares of IMRX opened at $4.99 on Wednesday. The stock has a 50-day moving average of $4.93 and a two-hundred day moving average of $5.21. Immuneering has a one year low of $2.90 and a one year high of $10.08. The stock has a market cap of $322.85 million, a P/E ratio of -4.26 and a beta of 0.38.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Analysts predict that Immuneering will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently modified their holdings of the stock. PVG Asset Management Corp purchased a new position in shares of Immuneering during the 1st quarter valued at about $773,000. Weiss Asset Management LP purchased a new position in shares of Immuneering during the 1st quarter valued at about $464,000. Cetera Investment Advisers purchased a new position in shares of Immuneering during the 1st quarter valued at about $67,000. Levin Capital Strategies L.P. purchased a new position in shares of Immuneering during the 1st quarter valued at about $53,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Immuneering during the 1st quarter valued at about $198,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.